Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

141. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database Full Text available with Trip Pro

Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database The aim of this study is to describe the trends and factors that influence the initial treatment of men with localized prostate cancer (PC) in the United States between 2004 and 2014.The National Cancer Institute's Surveillance, Epidemiology and End Results database was used to identify patients with primary prostate adenocarcinoma between 2004 and 2014. Patients were staged (...) in accordance with the American Joint Committee on Cancer 7th edition criteria and stratified according to the National Comprehensive Cancer Network guidelines risk group classification. Descriptive statistics describing treatment patterns by year of diagnosis, age, risk group, insurance status, and region were performed.A total of 460,311 male patients were identified with sufficient information to be categorized into National Comprehensive Cancer Network risk groups. Overall, 30.9% of patients had low

2018 Advances in radiation oncology

142. Current and Future Burden of Prostate Cancer in Songkhla, Thailand: Analysis of Incidence and Mortality Trends From 1990 to 2030 Full Text available with Trip Pro

Current and Future Burden of Prostate Cancer in Songkhla, Thailand: Analysis of Incidence and Mortality Trends From 1990 to 2030 Prostate cancer is the second most common malignancy among men worldwide, and it poses a significant public health burden that has traditionally been limited mostly to developed countries. However, the burden of the disease is expected to increase, affecting developing countries, including Thailand. We undertook an analysis to investigate current and future trends (...) of prostate cancer in the province of Songkhla, Thailand, using data from the Songkhla Cancer Registry from 1990 to 2013.Joinpoint regression analysis was used to examine trends in age-adjusted incidence and mortality rates of prostate cancer and provide estimated annual percent change (EAPC) with 95% CIs. Age-period-cohort (APC) models were used to assess the effect of age, calendar year, and birth cohort on incidence and mortality rates. Three different methods (Joinpoint, Nordpred, and APC) were used

2018 Journal of global oncology

143. Targeting protein myristoylation for the treatment of prostate cancer Full Text available with Trip Pro

Targeting protein myristoylation for the treatment of prostate cancer 29556510 2018 11 14 2331-4737 5 1-2 2018 Jan Oncoscience Oncoscience Targeting protein myristoylation for the treatment of prostate cancer. 3-5 10.18632/oncoscience.391 Sulejmani Essilvo E Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens,Athens, GA 30602, USA. Cai Houjian H Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia (...) , Athens,Athens, GA 30602, USA. eng R01 CA172495 CA NCI NIH HHS United States Editorial 2018 01 22 United States Oncoscience 101636666 2331-4737 B13 N-myristoyltransferase Src kinase myristoyl-CoA prostate cancer CONFLICTS OF INTEREST E. Sulejmani and H. Cai have no conflicts of interest to report. 2018 01 15 2018 01 15 2018 3 21 6 0 2018 3 21 6 0 2018 3 21 6 1 epublish 29556510 10.18632/oncoscience.391 391 PMC5854285 Nat Commun. 2014 Sep 26;5:4919 25255805 J Biol Chem. 2017 Nov 10;292(45):18422-18433

2018 Oncoscience

144. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. Full Text available with Trip Pro

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age.Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate their effects on age (...) at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated for these men to test prediction

2018 BMJ

145. Erleada for Castrate Resistant Prostate Cancer - Details

Erleada for Castrate Resistant Prostate Cancer - Details Erleada for Castrate Resistant Prostate Cancer - Details | CADTH.ca Find the information you need Erleada for Castrate Resistant Prostate Cancer - Details Erleada for Castrate Resistant Prostate Cancer - Details Project Number pCODR 10133 Brand Name Erleada Generic Name Apalutamide Strength 60 mg Tumour Type Genitourinary Indication Castrate Resistant Prostate Cancer Funding Request non-metastatic castrate resistant prostate cancer (nm

2018 CADTH - Pan Canadian Oncology Drug Review

146. ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer. Full Text available with Trip Pro

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer. Most prostate cancer patients develop castration-resistant prostate cancer (CRPC) after androgen deprivation therapy treatment. CRPC growth is mediated mostly by androgen receptor signalling driven by primary androgens synthesised largely by the CYP17A1 enzyme.To evaluate the safety profile and dose-limiting toxicities of ODM-204 (...) looked at the safety of ODM-204, a novel dual inhibitor of CYP17A1 and the androgen receptor, in castration-resistant prostate cancer patients. ODM-204 treatment was found to be well tolerated, and it also reduced both serum testosterone and prostate-specific antigen levels, but the properties of the molecule prevent further development.Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2018 European urology focus Controlled trial quality: uncertain

147. Screening for Prostate Cancer*

has published a white paper to provide some guidance regarding periprocedural prophylaxis. Since prostate biopsies are also an important part of some active surveillance programs, understanding these risks and communicating them to patients is not only integral to informed consent for prostate cancer screening but also for consideration of treatment options. Once diagnosed with prostate cancer, a man is faced with the risk of overtreatment of indolent disease due to the assumption that diagnosis (...) with a malignancy must necessarily result in treatment of this malignancy. Estimates of overdiagnosis vary widely from less than 5% to more than 75% depending upon the population used with lead times of 5 to 15 years. Although prostate cancer specific mortality and the need for related palliative care is decreased by screening, quality of life may be impaired as a result due to lasting impairment in urinary, bowel, and sexual function. There is considerable distress involved in the decision making process

2018 National Guideline Clearinghouse (partial archive)

148. Prostate cancer

5-year survival rate is around 100% for local- and regional-stage prostate cancer, and around 30% for distant-stage prostate cancer (based on data from 2007 to 2013). Definition A malignant tumour of glandular origin, situated in the prostate. It is most commonly seen in older men; between 2011 and 2015 the median age at diagnosis in the US was 66 years. National Cancer Institute; Surveillance, Epidemiology, and End Results program (SEER). SEER stat fact sheets: prostate cancer. 2018 [internet (...) is the principal investigator of an R-21 NIH research grant investigating the tumour-mediated immune responses in African-American men with prostate cancer. Professor Department of Radiation Oncology University of Texas MD Anderson Cancer Center Houston TX Disclosures MSA declares that he has no competing interests. Peer reviewers Clinical Oncology Registrar St Luke's Cancer Centre Royal Surrey Hospital Guildford Surrey UK Disclosures EA has received consultation fees from the following organisations during

2018 BMJ Best Practice

149. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph (Abstract)

) until disease progression, unacceptable toxicity, or the completion of ten treatment cycles. Randomisation was stratified by use of opioids for prostate cancer-related pain at screening, disease progression following first-line docetaxel treatment established by radiographic evidence, and previous treatment with abiraterone or enzalutamide. The co-primary endpoints were overall survival in all randomly assigned patients and in a poor-prognosis subgroup. All analyses were intention to treat (...) Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph Docetaxel and cabazitaxel improve overall survival compared with mitoxantrone in patients with metastatic castration-resistant prostate cancer. Custirsen (OGX011) is a second generation highly specific antisense oligonucleotide that inhibits

2018 EvidenceUpdates

150. Prostate cancer screening with prostate-specific antigen (PSA) test Full Text available with Trip Pro

imaging (MRI), bone scan, and computed tomography, are often also performed, especially in men presenting with higher risk disease, to check for disease spread. Screening controversy For many reasons, PSA screening remains controversial. Advocates often base their opinions on the European Randomised study of Screening for Prostate Cancer (ERSPC), which suggests that screening may reduce the long term risk of prostate cancer-specific mortality by at least 9% (relative reduction). They also note (...) that substantial observational evidence indicates a reduction in advanced disease and reduction in prostate cancer mortality, which they attribute to the introduction of PSA screening. Opponents of PSA screening highlight the indolent natural course of prostate cancer, citing systematic reviews that reported little or no impact of PSA screening on overall and prostate cancer-specific mortality. Opponents also suggest that the harms and burden from overdiagnosis and overtreatment resulting in unnecessary

2018 BMJ Rapid Recommendations

151. High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer

the disease, while preserving continence and, if possible, potency [1] (B0001). Radiation therapy (RT) is another definitive treatment strategy in which a therapeutic dose of radi- ation is delivered to the tumour (either as external beam, brachytherapy, or a combination of both) while minimising the radiation to normal tissue. External beam RT (EBRT) utilises an external source of radiation to treat the prostate gland and a margin of adjacent normal tissue. Brachy- therapy directly implants a radioactive (...) source within the prostate, thus providing the highest dose of radiation. Its aim is to maximise irradiation of the tumour while minimising radiation to normal tissue [11] (B0001). Health problem PCa is the most common non-skin cancer in men in Europe [1]. Localised PCa is often indolent, and has no impact on health, even without treatment [12-14] (A0002). The incidence of PCa is higher in Northern and Western Europe compared with other areas of Europe, whereas incidence rates in Eastern and Southern

2018 EUnetHTA

152. Management of locally advanced and metastatic prostate cancer

cancer. Sydney: Cancer Council Australia. [Version URL: , cited 2019 May 26]. Available from: . Management of locally advanced and metastatic prostate cancer Contents Download Clinical questions: Androgen deprivation therapy (ADT) Radiotherapy Radiotherapy and androgen deprivation therapy (ADT) Surgery Surgery plus androgen deprivation therapy Pathologic T3/T4 disease post radical surgery (Patients with extra capsular extension, seminal vesicle involvement or positive surgical margins) Node-positive (...) Management of locally advanced and metastatic prostate cancer Management of locally advanced and metastatic prostate cancer - Cancer Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions Cite this guideline Cancer Council Australia Advanced Prostate Cancer Guidelines Working Party. Management of locally advanced and metastatic prostate

2018 Cancer Council Australia

153. Prostate Cancer: Screening

common types of cancer that affects men. In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 11%, and the lifetime risk of dying of prostate cancer is 2.5%. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. In autopsy studies of men who died of other causes, more than 20% of men aged 50 to 59 years and more than 33% of men aged 70 to 79 years were found to have prostate cancer. In some (...) . The CAP trial was a cluster-randomized trial of a single invitation to PSA-based screening in the United Kingdom among 415,357 men. Overall, 34% of invited men received a valid PSA screening test. After a median follow-up of 10 years, there was no significant difference in prostate cancer mortality between the invited group and the control group (absolute risk, 0.30 per 1000 person-years vs 0.31 per 1000 person-years, respectively). Based on clinical stage, tumor grade, and PSA level, prostate cancer

2018 U.S. Preventive Services Task Force

154. Post-treatment impact and needs of prostate cancer survivors in Malaysia; a qualitative study Full Text available with Trip Pro

Post-treatment impact and needs of prostate cancer survivors in Malaysia; a qualitative study There are limited studies conducted on the needs of cancer survivors in developing countries like Malaysia. This qualitative study aimed at exploring the post-treatment impact and needs of prostate cancer survivors.A qualitative study design was used. One in-depth interview and four focus group discussions were conducted with 24 prostate cancer survivors (age range: 58-79 years) from government (...) and private hospitals in Malaysia in 2013. Trained researchers used a topic guide to guide the interviews, which were audio-recorded, transcribed verbatim, checked and managed with Nvivo 10 software. A thematic approach was used to analyse the data.Three main themes emerged from the analysis: (a) impact of prostate cancer on the survivors, (b) support needed for coping and (c) information needs. Prostate cancer has an important impact on the survivors' lifestyle after treatment. Some of them have to live

2017 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

155. Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer Full Text available with Trip Pro

Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer The purpose of this study is to report the long-term outcomes and toxicity results of a prospective trial of moderately hypofractionated, image guided radiation therapy (RT) for localized prostate cancer.Patients were enrolled between December 2006 and February 2012. Patients in group 1 were stage T1-T2b, had a Gleason score (GS) of 2 to 6 or 7 (3 + 4) with only 1 lobe involved (...) , and had prostate-specific antigen levels ≤10 ng/mL. Group 2 patients were stage ≥T2c, had a GS ≥7 (4 + 3), a GS 7 (3 + 4) involving both lobes, or a PSA >10 ng/mL and ≤30 ng/mL. All patients underwent transrectal ultrasound guided fiducial (Visicoil) placement prior to computed tomography/magnetic resonance imaging simulation. Daily cone beam computed tomography with online correction was used. The prescribed dose was 64 Gy in 20 fractions. The primary endpoint was acute and late toxicity

2017 Advances in radiation oncology

156. Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer Full Text available with Trip Pro

Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer 29344555 2018 11 13 2331-4737 4 11-12 2017 Nov Oncoscience Oncoscience Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer. 175-177 10.18632/oncoscience.389 Narayanan Ramesh R University of Tennessee Health Science Center, Memphis, TN, USA. Ponnusamy Suriyan S University of Tennessee Health Science Center, Memphis, TN, USA. Miller Duane D DD University of Tennessee (...) Health Science Center, Memphis, TN, USA. eng Editorial 2017 12 28 United States Oncoscience 101636666 2331-4737 androgen receptor castration-resistant prostate cancer (CRPC) selective androgen receptor degraders (SARDs) ubiquitin proteasome pathway CONFLICTS OF INTEREST Ramesh Narayanan is a consultant of GTx, Inc. 2017 11 16 2017 11 16 2018 1 19 6 0 2018 1 19 6 0 2018 1 19 6 1 epublish 29344555 10.18632/oncoscience.389 389 PMC5769981 Elife. 2013 Apr 09;2:e00499 23580326 Science. 2009 May 8;324(5928

2017 Oncoscience

157. Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis Full Text available with Trip Pro

Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis For high-risk prostate cancer (HR-PCa) in men with a life expectancy of at least 10 years, the National Comprehensive Cancer Network recommends radiation therapy (RT) plus androgen deprivation therapy (ADT) with category 1 evidence or radical prostatectomy (RP) as an acceptable initial therapy. Randomized (...) evidence regarding which therapy is optimal for disease control is lacking for men with HR-PCa. We performed a propensity-score-matched comparison of outcomes for men with localized HR-PCa treated with primary RT or RP.The medical records of patients with localized HR-PCa who were treated at our institution between 2002 and 2011 were reviewed. Patient and disease characteristics, treatment details, and outcomes were collected. A combination of nearest-neighbor propensity score matching on age, Adult

2017 Advances in radiation oncology

158. Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital Full Text available with Trip Pro

Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital Understanding the drivers of delays from diagnosis to treatment can elucidate how to reduce the time to treatment (TTT) in patients with prostate cancer. In addition, the available treatments depending on the stage of cancer can vary widely for many reasons. This study investigated the relationship of TTT and treatment choice (...) with sociodemographic factors in patients with prostate cancer who underwent external beam radiation therapy (RT), radical prostatectomy (RP), androgen deprivation therapy (ADT), or active surveillance (AS) at a safety-net academic medical center.A retrospective review was performed on 1088 patients who were diagnosed with nonmetastatic prostate cancer between January 2005 and December 2013. Demographic data as well as data on TTT, initial treatment choice, American Joint Committee on Cancer stage, and National

2017 Advances in radiation oncology

159. Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study Full Text available with Trip Pro

Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study Purpose To determine the effect of comorbidity on prostate cancer (PCa)-specific mortality across treatment types. Patients and Methods These are the results of a population-based observational study in Sweden from 1998 to 2012 of 118,543 men who were diagnosed with PCa with a median follow-up of 8.3 years (interquartile range, 5.2 to 11.5 years) until death from PCa or other causes. Patients were (...) categorized by patient characteristics (marital status, educational level) and tumor characteristics (serum prostate-specific antigen, tumor grade and clinical stage) and by treatment type (radical prostatectomy, radical radiotherapy, androgen deprivation therapy, and watchful waiting). Data were stratified by Charlson comorbidity index (0, 1, 2, or ≥ 3). Mortality from PCa and other causes and after stabilized inverse probability weighting adjustments for clinical patient and tumor characteristics

2017 EvidenceUpdates

160. Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms

the Committee, issued a positive opinion for granting a marketing authorisation to Tookad on 14 September 2017. 2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy = 10 years and: - Clinical stage T1c or T2a, - Gleason Score = 6, based on high-resolution biopsy strategies, - PSA = 10 ng/mL, - 3 positive cancer cores (...) Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 September 2017 EMA/644309/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report TOOKAD International non-proprietary name: padeliporfin Procedure No. EMEA/H/C/004182/0000 Note Assessment report

2017 European Medicines Agency - EPARs